Advantage Alpha Capital Partners LP Takes Position in Guardant Health, Inc. (NASDAQ:GH)

Advantage Alpha Capital Partners LP bought a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 14,937 shares of the company's stock, valued at approximately $343,000.

A number of other hedge funds have also recently made changes to their positions in GH. Sumitomo Mitsui Trust Group Inc. grew its position in Guardant Health by 1,282.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock worth $28,128,000 after acquiring an additional 1,137,482 shares in the last quarter. First Light Asset Management LLC increased its position in shares of Guardant Health by 119.7% during the 2nd quarter. First Light Asset Management LLC now owns 416,967 shares of the company's stock valued at $12,042,000 after purchasing an additional 227,202 shares during the last quarter. International Assets Investment Management LLC raised its holdings in shares of Guardant Health by 2,193.9% during the 3rd quarter. International Assets Investment Management LLC now owns 10,208 shares of the company's stock valued at $2,340,000 after buying an additional 9,763 shares in the last quarter. Sei Investments Co. bought a new stake in Guardant Health in the 2nd quarter worth approximately $831,000. Finally, SG Americas Securities LLC purchased a new stake in Guardant Health in the third quarter worth approximately $1,029,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Meghan V. Joyce sold 2,896 shares of the company's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is owned by corporate insiders.

Guardant Health Stock Up 2.0 %

Shares of GH traded up $0.69 during trading hours on Wednesday, hitting $35.06. The company had a trading volume of 237,645 shares, compared to its average volume of 2,069,748. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of -8.25 and a beta of 1.11. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $37.04. The firm has a fifty day moving average price of $24.61 and a 200-day moving average price of $27.14.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million during the quarter, compared to analysts' expectations of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. Guardant Health's revenue was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.73) earnings per share. On average, equities research analysts forecast that Guardant Health, Inc. will post -3.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GH has been the topic of a number of recent research reports. UBS Group raised their price objective on Guardant Health from $32.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, August 21st. JPMorgan Chase & Co. lifted their price target on Guardant Health from $48.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Citigroup increased their price objective on Guardant Health from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. Piper Sandler lifted their target price on shares of Guardant Health from $30.00 to $34.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 13th. Finally, The Goldman Sachs Group raised their price target on shares of Guardant Health from $32.00 to $36.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.60.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.